Health & Biotech
IPO Watch: Invex Pharma wants to use a diabetes drug to treat brain injuries
Chinese cannabis? It’s complicated…but it’s coming
Health: PainChek wants to know if its app can detect pain in babies
Pot: Zelda gets the go-ahead for cannabis test to treat opiate addictions
Probiotec shares just hit their highest point in nearly a decade
Dr Boreham’s Crucible: ‘Robust’ biotech and Kerry Stokes as a backer, so what’s holding down Patrys’ share price?
Rhinomed will explore links between poor sleep and suicide in new study
Check up: What’s happening with ASX small cap health stocks? They’re up 11 pc this year
Phylogica just scored a key win for its patented eye treatment technology
Health: Bionomics can’t get its anxiety drug to stick; shares dive 31pc
What is regenerative medicine? Cynata’s CEO explains
Performance-enhancing bacteria give athletes – and mice – an extra edge
Health: Hear that? Nuheara is in play after someone tried to take it over
In a tough economy who do you call? Health stocks
Health: OpenDNA establishes China gateway for Petrus Pharmaceuticals
MGC takes a Euro trip and hits Germany with a brand new dist deal
Health: Althea scores first UK customer, eyes off local processing facility
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
